Melissa Epperly - Jul 1, 2021 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Financial Officer
Signature
By: /s/ Melissa B. Epperly
Stock symbol
ZNTL
Transactions as of
Jul 1, 2021
Transactions value $
-$158,054
Form type
4
Date filed
7/6/2021, 08:01 PM
Previous filing
Jun 14, 2021
Next filing
Aug 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale -$35.1K -700 -0.27% $50.10 259K Jul 1, 2021 Direct F1, F2
transaction ZNTL Common Stock Sale -$70.5K -1.38K -0.53% $51.15 258K Jul 1, 2021 Direct F1, F3
transaction ZNTL Common Stock Sale -$41.9K -805 -0.31% $52.01 257K Jul 1, 2021 Direct F1, F4
transaction ZNTL Common Stock Sale -$10.6K -200 -0.08% $53.19 257K Jul 1, 2021 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.68 to $50.58. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.71 to $51.57. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.83 to $52.39. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.15 to $53.22. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.